Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cyclo Therapeutics (CYTH – Research Report), CytomX Therapeutics (CTMX – Research Report) and Pacific Biosciences (PACB – Research Report).
Cyclo Therapeutics (CYTH)
Cyclo Therapeutics received a Buy rating and a $2.60 price target from Ascendiant analyst Lucas Ward today. The company’s shares closed last Friday at $1.16.
According to TipRanks.com, Ward is ranked #8661 out of 8786 analysts.
Currently, the analyst consensus on Cyclo Therapeutics is a Moderate Buy with an average price target of $3.30.
See today’s best-performing stocks on TipRanks >>
CytomX Therapeutics (CTMX)
J.P. Morgan analyst Anupam Rama upgraded CytomX Therapeutics to Hold today. The company’s shares closed last Friday at $1.67.
According to TipRanks.com, Rama is a 4-star analyst with an average return of
Currently, the analyst consensus on CytomX Therapeutics is a Hold with an average price target of $3.06.
Pacific Biosciences (PACB)
J.P. Morgan analyst Rachel Vatnsdal maintained a Hold rating on Pacific Biosciences yesterday. The company’s shares closed last Friday at $1.55, close to its 52-week low of $1.25.
According to TipRanks.com, Vatnsdal has 0 stars on 0-5 stars ranking scale with an average return of
Pacific Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.15, which is a 250.3% upside from current levels. In a report issued on April 16, Nephron also downgraded the stock to Hold with a $2.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYTH:
